About Us
Company Profile
Vision Values & Promise
Management
Board of Directors
Executive Leadership Team
Locations Worldwide
Subsidiaries
Group Ombudsperson
Business Segments
Radiopharma
Allergy Immunotherapy
CDMO Sterile Injectables
Contract Research Development & Manufacturing Organisation
Drug Discovery Service
Active Pharmaceutical Ingredients
Generics
Proprietary Novel Drugs
Business Enablers
Manufacturing
R&D and Intellectual Property
Business Excellence
Human Resource
Supply Chain
Investors
Financials
Quarterly Results
Investor Presentation
Annual Reports
Annual Return
Subsidiaries Accounts
Intimation to Stock Exchanges
Jubilant Pharmova Investor Meets
Stock Information
Share Price Graph
Historical Share Price
Analyst Coverage
Listing
Sub Division of Shares
Equity History
Investor Information
Change of Name
Scheme of Arrangement
Share Holding Pattern
Share Transfer Information
Distribution Pattern
Dividend Payment
Cost Spilit Letter
FAQs
Forms
Updation of KYC details
Credit Ratings
Corporate Governance
Philosophy
Board Structure
Policies and Codes
Duties of Directors
Postal Ballot
Unclaimed Dividend & Shares
Investor Feedback Form
Investor Contact
Nodal Officer
Institutional Investors
Investor Grievances
Registrar and Transfer Agent
KMP - Reg. 30
Investors Meet
Disclosure
Online Dispute Resolution
Sustainability
Overview
Corporate Social Responsibility
Sustainable Development Goals
Safety and Occupational Health
Stakeholder Engagement
Environment
Environmental Compliance
Fly Ash Stock Report
Policies
Climate Change Mitigation and Energy Conservation Policy
Environmental, Health and Safety Policy
Sustainability Policy
Biodiversity Policy
Biomedical Waste Information
Sustainability Report
Sustainability Contact
About Us
Company Profile
Vision Values & Promise
Management
Board of Directors
Shyam S Bhartia
Hari S Bhartia
Sushil Kumar Roongta
Vivek Mehra
Arun Seth
Shirish G. Belapure
Shivpriya Nanda
Harsh Mahajan
Priyavrat Bhartia
Arjun Shanker Bhartia
Arvind Chokhany
Dr. Ramakrishnan Arul
Executive Leadership Team
Locations Worldwide
Subsidiaries
Group Ombudsperson
Business Segments
Radiopharma
Allergy Immunotherapy
CDMO Sterile Injectables
Contract Research Development & Manufacturing Organisation
Drug Discovery Service
Active Pharmaceutical Ingredients
Generics
Proprietary Novel Drugs
Business Enablers
Manufacturing
R&D and Intellectual Property
Business Excellence
Human Resource
Supply Chain
Investors
Financials
Quarterly Results
Investor Presentation
Annual Reports
Annual Return
Subsidiaries Accounts
Intimation to Stock Exchanges
Jubilant Pharmova Investor Meets
Stock Information
Share Price Graph
Historical Share Price
Analyst Coverage
Listing
Sub Division of Shares
Equity History
Investor Information
Change of Name
Scheme of Arrangement
Share Holding Pattern
Share Transfer Information
Distribution Pattern
Dividend Payment
Cost Spilit Letter
FAQs
Forms
Updation of KYC details
Credit Ratings
Corporate Governance
Philosophy
Board Structure
Policies and Codes
Policy on Materiality of Related Party Transactions and Dealing with Related Party Transactions
Policy on Board Diversity
Policy for Determining Material Subsidiaries
Whistle Blower Policy
Corporate Social Responsibility Policy
Code of Conduct for Directors and Senior Management
Code for Independent Directors
Appointment and Remuneration Policy
Familiarisation Programme for Independent Directors
Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information
Policy for Determination of Materiality of Events and Information
Archival Policy
Dividend Distribution Policy
Silent Period Policy
Corporate Tax Policy
Grievance Redressal policy
Risk Management Policy
Duties of Directors
Independence Criteria for Directors
Postal Ballot
Unclaimed Dividend & Shares
Investor Feedback Form
Investor Contact
Nodal Officer
Institutional Investors
Investor Grievances
Registrar and Transfer Agent
KMP - Reg. 30
Investors Meet
Disclosure
Online Dispute Resolution
Sustainability
Overview
Corporate Social Responsibility
Sustainable Development Goals
Safety and Occupational Health
Stakeholder Engagement
Environment
Environmental Compliance
Fly Ash Stock Report
Policies
Climate Change Mitigation and Energy Conservation Policy
Environmental, Health and Safety Policy
Sustainability Policy
Biodiversity Policy
Biomedical Waste Information
Sustainability Report
Sustainability Contact
News
Careers
Global Opportunities
Code of Conduct
Fraud Alert Statement
Fun at Work
Diversity and Inclusion
Campus Hiring
Policies
Downloads
Brochures
Annual Report
Sustainability Report
Contact
Addresses
Enquiry Form
News
Careers
Global Opportunities
Code of Conduct
Fraud Alert Statement
Fun at Work
Diversity and Inclusion
Campus Hiring
Policies
Downloads
Brochures
Annual Report
Sustainability Report
Contact
Addresses
Enquiry Form
What are you looking for?
×
Investors
Home
Investors
Intimation to Stock Exchanges
Intimation to Stock Exchanges
Intimation to Stock Exchanges 2024 - 25
Q4 2024-25
Trading Window Closure – March 24, 2025
Update on Acquisition of Stake in Jasmin – March 20, 2025
Clarification on news articles - February 25, 2025
Stock Exchange Disclosure Audio Recording - February 24, 2025
Jubilant Pharmova Stock Exchange Disclosure - February 24, 2025
Investors Meet – February 10, 2025
Newspaper publication of Financial Results – February 1, 2025
Press Release and Presentation Q3 Results FY 2025 – January 31, 2025
Prepayment of loan - USD 25 million (24.01.2025)
Investors Meet – February 24, 2025
Intimation of Board Meeting – January 31, 2025
USFDA Communication – Cadista- January 16, 2025
Q3 2024-25
Credit Rating – December 10, 2024
Deferment of Investors Meet – November 12, 2024
Newspaper publication of Financial Results – October 26, 2024
Press Release and Presentation Q2 Results FY 2025 – October 25, 2024
Q2 Results FY 2025 – October 25, 2024
Acquisition of Stake in Jasmin – October 4, 2024
Q2 2024-25
Trading Window Closure – September 30, 2024
USFDA Communication – Montreal – September 28, 2024
USFDA Communication – Spokane – September 26, 2024
Investors Meet – September 19, 2024
USFDA Communication – Spokane – September 10, 2024
46th AGM Proceedings, Voting Results and Scrutinizer’s Report
ESOP Certificate
Outcome of Postal Ballot – Appointment of Dr. Ramakrishnan Arul and Amendment of Jubilant Pharmova Employees Stock Option Plan 2018 and Approval for Grant of Employee Stock Options and/or Restricted Stock Units to the Employees of the Subsidiary Companies (23.08.2024)
Investors Meet – August 22, 2024 and August 23, 2024
Stock Exchange disclosure – Signing of ‘Put Option Offer’ between Jubilant Biosys Innovative Research Services Pte Limited and Pierre Fabre Laboratories– 16.08.2024
Stock Exchange disclosure for resignation of Senior Management Personnel – August 2, 2024
Stock Exchange disclosure for receipt of orders from Income Tax Department w.r.t. Jubilant Generics Limited – 27.07.2024
Newspaper publication of Financial Results – July 20, 2024
USFDA Communication - Montreal – July 19, 2024
Press Release and Presentation Q1 FY 2025 – July 19, 2024
Q1 Results FY 2025 – July 19, 2024
Q1 2024-25
Outcome of Postal Ballot – Change in Board Members (26.06.2024)
Completion of prepayment of loan - USD 75 million (25.06.2024)
Trading Window Closure – June 23, 2024
Newspaper Advertisement for dispatch of communication sent to shareholders relating to notice of transfer of equity shares to Investor Education and Protection Fund
USFDA Communication – Montreal (18.06.2024)
Investor Meet - June 18, 2024
Investment to expand PET Radiopharmacy Network (14.06.2024)
Prepayment of loan - USD 75 million (14.06.2024)
USFDA communication Spokane - June 07, 2024
Update on Acquisition of stake in O2 Renewable Energy XVI Private Limited - June 06, 2024
Update on Jubilant Pharmova Disclosure (Sofie) - June 05, 2024
Q4 Results FY 2024 - May 29, 2024
Declaration of Dividend - May 29, 2024
Change of Directors - May 29, 2024
Acquisition of Stake in Isharays Energy Two Private Limited - May 28, 2024
Newspaper Advertisement for dispatch of Postal Ballot Notice – May 27, 2024
Appointment of Mr. Harsher Singh as CEO of Radiopharma Business
Update on Stock Exchange disclosure for receipt of orders from Income Tax Department
USFDA Audit Updates - April 24, 2024
Jubilant Cadista Disclosure - April 18, 2024
USFDA Communication - April 17, 2024
Stock exchange disclosure for receipt of orders from Income tax department
Update on acquisition of stake in O2 Renewable Energy XVI Private Limited
Intimation to Stock Exchanges 2023 - 24
Q4 2023-24
Change in Independent Directors of the Company
Credit Rating – 22.03.2024
Investor Meet – March 12, 2024 – Update
Investor Meet – March 12, 2024
Newspaper publication of Financial Results – February 03, 2024
USFDA Communication – February 02, 2024
Outcome of Postal Ballot – Appointment of Mr. Jinang Pratap Parekh as a Director and Whole-Time Director of the Company
Jubilant Pharmova Disclosure (Sofie) - January 28, 2024
Intimation of Board Meeting – February 02, 2024
Acquisition of Stake in O2 Renewable Energy XVI Private Limited – January 2, 2024
Q3 2023-24
Q3 Results FY 2024 – February 02, 2024
Press Release and Presentation Q3 FY 2024 - February 02, 2024
Newspaper Advertisement for dispatch of Postal Ballot Notice – December 26, 2023
Trading Window Closure – December 26, 2023
Postal Ballot Notice – December 21, 2023
USFDA Communication – November 10, 2023
Newspaper publication of Financial Results- October 28, 2023
Press Release and Presentation Q2 FY 2024 - October 27, 2023
Q2 Results FY 2024 – October 27, 2023
Intimation of Board Meeting - October 27, 2023
Q2 2023-24
Trading Window Closure - September 25, 2023
Re-appointment of Mr. Arun Seth as Independent Director
Appointment of M/s. Walker Chandiok & Co. LLP as Statutory Auditors
45th AGM proceedings, Voting Results and Scrutinizers’ Report
Outcome of Postal Ballot- Appointment of Mr. Priyavrat Bhartia as Managing Director and appointment of Mr. Arjun Bhartia as Joint Managing Director
Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2022-23
Newspaper Advertisement for communication to shareholders on deduction of tax at source on dividend
Disclosure of continuing event or information (i.e. ongoing litigations) of the Company and its subsidiaries under Regulation 30
AGM Notice and Annual Report 2022-23
Intimation of Record Date for the purpose of Declaration of Dividend for FY 2022-23
Newspaper Advertisement for Dispatch of Postal Ballot - July 22, 2023
Newspaper Advertisement for Financial Results - July 20, 2023
Postal Ballot Notice - July 20, 2023
ESOP Disclosure - July 19, 2023
Q1 Results FY 2024 - July 19, 2023
Press Release and Presentation Q1 FY 2024 - July 19, 2023
Newspaper Advertisement – Notice of Transfer of Equity Shares to Investor Education and Protection Fund
Q1 2023-24
Notice of Board Meeting - June 26, 2023
Trading Window Closure - June 23, 2023
Investor Meet - May 30, 2023
Change of Directors and CFO - May 30, 2023
USFDA Communication - May 29, 2023
Q4 Results FY 2023 - May 29, 2023
Declaration of Dividend - May 29, 2023
Notice of Board Meeting - May 21, 2023
Outcome of Postal Ballot - Appointment of Mr. Shirish G. Belapure as an Independent Director - April 13, 2023
Intimation to Stock Exchanges 2022 - 23
Q4 2022-23
Intimation regarding Closure of Trading Window - March 24, 2023
Loan Facility by Government of Canada - March 16, 2023
Newspaper Advertisement for Dispatch of Postal Ballot - March 14, 2023
Postal Ballot Notice - March 13, 2023
Appointment of Director - March 8, 2023
USFDA Communication - March 8, 2023
Stock Exchange Disclosure Con-call transcript - February 9, 2023
Appointment of Statutory Auditors - February 4, 2023
Newspaper Advertisement for Financial Results - February 4, 2023
Investor Call Audio Recording - February 3, 2023
Q3 Results FY 2023 - February 3, 2023
Revised Con Call Invite - February 1, 2023
USFDA Approval - January 31, 2023
Investors’ Con-Call Intimation - January 27, 2023
Notice of Board Meeting - January 25, 2023
Q3 2022-23
Credit Rating - December 27, 2022
Trading Window Closure - December 23, 2022
Press release - December 14, 2022
Clarification to NSE - December 12, 2022
Newspaper advertisement for loss of Share Certificates - December 5, 2022
Jubilant Pharmova Employees Stock Option Plan 2018 - Grant of Stock Options - November 17, 2022
Outcome of Postal Ballot - Amendment of Jubilant Pharmova Employees Stock Option Plan 2018 - November 14, 2022
Stock Exchange Disclosure Con-call transcript - October 31, 2022
Press Release - October 29, 2022
Newspaper advertisement for financial results - October 22, 2022
Investor Call Audio Recording - October 22, 2022
Q2 Results FY 2023 - October 21, 2022
Newspaper Publication of Postal Ballot Notice - October 17 2022
Notice of Postal Ballot - October 15, 2022
Notice of Board Meeting - October 13, 2022
Investors’ Con-call Intimation - October 13, 2022
Q2 2022-23
Voting Results of Annual General Meeting - September 26, 2022
Intimation of Trading Window Closure - September 23, 2022
Appointment of Dr. Jaidev Rajpal as Head of Generics business
Newspaper advertisement for dispatch of AGM Notice - September 4, 2022
AGM Notice and Annual Report 2021-22
USFDA Communication - August 26, 2022
Early Redemption of Senior Notes Due in 2024 by Jubilant Pharma Limited
Stock Exchange Disclosure Con- Call Transcript- August 8, 2022
Newspaper publication of Financial Results - August 05, 2022
Investor Call Audio Recording - August 2, 2022
Grant of ESOP - August 2, 2022
USFDA Audit - August 2, 2022
Q1 Results FY 2023 - August 2, 2022
Notice of Board Meeting - August 2, 2022
Investors’ Con-call Intimation - August 2, 2022
Early Redemption of 6% Senior Notes by Jubilant Pharma Limited
Intimation of Dividend Record Date - July 29, 2022
Loan agreement with Standard Chartered Bank - July 13, 2022
USFDA Communication - July 13, 2022
Clarification regarding Volume - July 08, 2022
Newspaper Publication w.r.t. Notice of Transfer of shares to IEPF - July 01, 2022
Appointment of WTD - July 1, 2022 and CS - August 1, 2022
Q1 2022-23
Expansion of CMO Manufacturing facility at Montreal, Canada and Government of Quebec funding through a loan
Trading Window Closure - June 23, 2022
NCLT Final Order - June 13, 2022
Letter to SEs - Transcript of Earnings Conference Call BM - June 2, 2022
Investors’ Meet - June 1, 2022
Newspaper Advertisement for Financial Results - May 28, 2022
Stock Exchange Intimation Audio Recording May 28, 2022
Cooperative agreement of US$149.6 Million with US Government - May 28, 2022
Q4 Results FY 2022 - May 27, 2022
Dividend FY 2022 - May 27, 2022
NCLT Order Scheme of Arrangement - May 25, 2022
Intimation of Board Meeting - May 20, 2022
Schedule of Investor Conference Call - May 20, 2022
Outcome of Postal Ballot - Alteration of Articles of Association - May 17, 2022
Newspaper Advertisement for Dispatch of Postal Ballot - April 18, 2022
Postal Ballot Notice - April 16, 2022
Update on Investors/ Analysts Meeting
Investors’ Meet - April 4, 2022
Greencure Investment - April 2, 2022
Intimation to Stock Exchanges 2021 - 22
Q4 2021-22
Investors’ Meet - March 30, 2022
USFDA ANDA Approval - March 17, 2022
Investor Meet - March 14, 2022
Credit Rating - February 16, 2022
Newspaper Advertisement for Financial Results - February 5, 2022
Q3 Results FY 2022 - February 4, 2022
Notice of Board Meeting - January 27, 2022
Investors' Con-call Intimation - January 27, 2022
NCLT Convened Meetings - Proceedings and Scrutinizer Reports - January 15, 2022
Q3 2021-22
Trading Window Closure - December 24, 2021
Newspaper Advertisement - Notice of NCLT Convened Meetings - December 14, 2021
Notice of NCLT Convened Meeting of Equity Shareholders - December 10, 2021
Notice of NCLT Convened Meeting of Unsecured Creditors - December 10, 2021
Investors’ Meet - November 15, 2021
Groundbreaking Ceremony for expansion of Spokane Facility - November 11, 2021
Newspaper Advertisement for Financial Results - October 25, 2021
Q2 Results FY 2022 - October 22, 2021
Notice of Board Meeting - October 14, 2021
Investors’ Con-call Intimation - October 14, 2021
Q2 2021-22
Investor Meet - September 23, 2021
Trading Window Closure - September 23, 2021
Voting Results of Annual General Meeting - September 22, 2021
AGM Proceedings - September 22, 2021
Newspaper Advertisement for Dispatch of AGM Notice - August 31, 2021
Investors’ Meet - August 31, 2021
Newspaper Advertisement for Pre Dispatch AGM Notice - August 26, 2021
Investors’ Meet - August 21, 2021
Investors’ Meet - August 16, 2021
Intimation of Dividend Record Date - July 27, 2021
Newspaper Advertisement for Financial Results - July 25, 2021
Employees Stock Option Plan 2018 - July 23, 2021
Board approval for API Demerger - July 23, 2021
Q1 Results FY 2022 - July 23, 2021
Notice of Board Meeting - July 15, 2021
Investors’ Con-call Intimation - July 15, 2021
US FDA Import Alert on Roorkee Facility - July 15, 2021
Newspaper advertisement - Notice of transfer of equity shares to Investor Education and Protection Fund
Q1 2021-22
Investors’ Meet and Presentation - June 23, 2021
Closure of Trading Window - June 22, 2021
Investors’ Presentation - June 18, 2021
Manufacturing Partnership for COVID-19 Vaccine - June 15, 2021
Investor Meet Invite - June 10, 2021
Newspaper Advertisement for Financial Results - June 7, 2021
Q4 Results FY 2021 - June 4, 2021
Dividend FY 2021 - June 4, 2021
Expansion of Spokane Facility - May 31, 2021
Investors’ Con-call Intimation - May 28, 2021
Notice of Board Meeting - May 28, 2021
Update on Credit Ratings - May 27, 2021
Intimation of transfer of shares in physical mode in terms of SEBI Circular No. SEBI/ HO/MIRSD/DOS3/CIR/P/2018/139 dated November 6, 2018
JPL wins Bracco's Legal Appeals - May 8, 2021
NCD Transfer - Record Date Intimation - May 7, 2021
Update on Credit Ratings - May 7, 2021
Notice of publication in newspapers - April 21, 2021
Update on Remdesivir - April 19, 2021
Appointment of WTD and CFO - April 1, 2021
Intimation to Stock Exchanges 2020 - 21
Q4 2020-21
Closure of Trading Window - March 24, 2021
JPL Bonds Redemption - March 5, 2021
Newspaper Advertisement for Financial Results - February 6, 2021
Change in Directors - February 6, 2021
Q3 Results FY 2021 - February 5, 2021
Notice of Early Redemption of Bonds by JPL - February 3, 2021
Demerger and Change of Name - February 1, 2021
Newspaper Advertisement of Board Meeting - January 30, 2021
JPL Bonds Redemption - January 30, 2021
Investors’ Con-call Intimation - January 29, 2021
Notice of Board Meeting - January 29, 2021
Newspaper Advertisement - Notice of Record Date - January 22, 2021
Record Date for Demerger - January 21, 2021
Outcome of Restructuring Committee Meeting - January 18, 2021
Issue of Non-Convertible Debentures - January 14, 2021
Outcome of Restructuring Committee Meeting - January 8, 2021
NCLT Certified Order - January 6, 2021
Q3 2020-21
Notice of Partial Early Redemption of Bonds by JPL - December 30, 2020
Closure of Trading Window - December 24, 2020
Composite Scheme - NCLT Order - December 24, 2020
Investors Meet - December 14, 2020
Investors Meet - December 2, 2020
Issuance of Commercial Papers of Rs. 90 Crore - November 26, 2020
Stock Exchange Disclosure - Investor Meet - November 10, 2020
Newspaper Advertisement for Financial Results - November 5, 2020
Investment in Sofie - November 4, 2020
Stock Exchange Disclosure - Issue of NCDs - November 4, 2020
Q2 Results FY 2021 - November 4, 2020
Credit Rating - October 31, 2020
Board Meeting Newspaper Advertisement - October 29, 2020
Notice of Board Meeting - October 28, 2020
Investors’ Con-call Intimation - October 28, 2020
Issuance of Commercial Papers of Rs. 90 Crore - October 12, 2020
Issuance of Commercial Papers of Rs. 30 Crore - October 9, 2020
Q2 2020-21
Closure of Trading Window - September 22, 2020
Intimation of Investor Meet - September 22, 2020
Outcome of Annual General Meeting - September 11, 2020
Intimation of Newspapers Advertisement - September 5, 2020
Resignation of Chief Financial Officer - September 4, 2020
Q1 Results FY 2021 - September 4, 2020
Investors' Con-call Intimation - August 28, 2020
Newspaper Advertisements for AGM Notice and Annual Report for FY 2020 - August 20, 2020
Stock Exchange Disclosure - Intimation of Annual General Meeting - August 19, 2020
Stock Exchange Disclosure - Credit Rating - August 19, 2020
Stock Exchange Disclosure Commercial Papers - August 18, 2020
Stock Exchange Disclosure Pre Dispatch AGM Notice-Newspaper Advertisements - August 15, 2020
Stock Exchange Disclosure Intimation of Board Meeting-Newspaper Advertisements - August 15, 2020
Notice of Board Meeting - August 14, 2020
Outcome of NCLT Convened Meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors - August 9, 2020
Stock Exchange Disclosure launch of ‘JUBI-R’ (remdesivir) - August 3, 2020
Q1 2020-21
Stock Exchange Disclosure approval of ‘JUBI-R’ (remdesivir) - July 20, 2020
Submission to Stock Exchange - Newspaper Advertisements - Notice for NCLT Convened Meetings
Notice of NCLT Convened Meeting of Secured Creditors - July 3, 2020
Notice of NCLT Convened Meeting of Unsecured Creditors - July 3, 2020
Notice of NCLT Convened Meeting of Equity Shareholders - July 3, 2020
JLL Stx - Closure of Trading Window - June 23, 2020
Issuance of Commercial Papers of Rs. 50 Crore - June 19, 2020
Issuance of Commercial Papers of Rs. 50 Crore - June 12, 2020
Stock Exchange Disclosure Non Deal Roadshow - June 11, 2020
Stock Exchange Disclosure - Issue of NCDs - June 2, 2020
Stock Exchange Disclosure - Credit Rating - May 30, 2020
Q4 Results FY 2020 - May 29, 2020
Stock Exchange Disclosure - Approval of Issue of NCDs - May 29, 2020
Notice of Board Meeting - May 25, 2020
Schedule of Investor Conference Call - May 25, 2020
JLL Stock Exchange Disclosure - Agreement with Gilead May 12, 2020
Stock Exchange Disclosure Commercial Papers April 17, 2020
Stock Exchange Disclosure Credit Rating April 10, 2020
Intimation to Stock Exchanges 2019 - 20
Q4 2019-20
Stock Exchange Disclosure Investor Conference Call Invite March 31, 2020
Stock Exchange Disclosure receipt of EIR from USFDA March 31, 2020
Closure of Trading Window March 24, 2020
Outcome of Board Meeting - Declaration of Dividend - February 27, 2020
Intimation of Board Meeting and Window Closure - February 20, 2020
Newspaper Advertisement for Q3 Results FY 2020 - February 3, 2020
Q3 Results FY 2020 - January 31, 2020
Newspaper Advertisement for Board Meeting - January 24, 2020
Schedule of Investor Conference Call - January 23, 2020
Notice of Board Meeting - January 23, 2020
Redemption of NCDs - January 08, 2020
Q3 2019-20
Approval of Early Redemption of NCDs - December 30, 2019
Notice of Committee Meeting for Early Redemption of NCDs - December 11, 2019
Payment of Penalty to SEBI - November 23, 2019
JPL Early Redemption of Bonds - November 21, 2019
MOFCOM, China terminates anti-dumping duty - November 20, 2019
SAT order against the SEBI Adjudication Order - November 8, 2019
Credit Rating by India Ratings and Research - November 5, 2019
Credit Rating by CRISIL - November 1, 2019
Slump Sale of IBP Business to JGL - October 25, 2019
Approval of the Composite Scheme of Arrangement - October 25, 2019
Changes of KMP (CFO) - October 25, 2019
Q2 Results FY 2020 - October 25, 2019
USFDA Approval - October 22, 2019
Partial Early Redemption of Bonds by JPL - October 21, 2019
Schedule of Investor Conference Call - October 17, 2019
Notice of Board Meeting - October 17, 2019
Credit Ratig by India Ratings & Research - October 16, 2019
Q2 2019-20
Voting Results of 41st Annual General Meeting - September 26, 2019
Proceedings of 41st Annual General Meeting - September 25, 2019
Closure of Trading Window - September 23, 2019
Payment of Half yearly interest of NCDs - September 5, 2019
News Paper Advertisements for 41st AGM - September 2, 2019
Notice for Record date and Interest payment on NCDs - August 8, 2019
Issuance of Commercial Paper of Rs. 40 Crore - August 2, 2019
Notice for Payment of Interest on NCDs - July 29, 2019
Newspaper Advertisement for Q1 Results FY 2020 - July 29, 2019
Q1 Results FY 2020 - July 26, 2019
JLL Restructuring - July 26, 2019
Newspaper Advertisement for Board Meeting - July 22, 2019
Schedule of Investor Conference Call - July 19, 2019
Notice of Board Meeting - July 19, 2019
10% price increase for Vitamin B3 (Niacin and Niacinamide) - July 15, 2019
Notice for Record date and Interest payment on NCDs - July 2, 2019
Q1 2019-20
Issuance of Commercial Paper of Rs. 40 Crore - June 25, 2019
Notice for closure of Trading Window - June 21, 2019
RPT Disclosure for FY 2019 - June 13, 2019
Disclosre regarding transfer of shares of JBL - June 7, 2019
Newspaper Advertisement for Audited Consoldated results for FY 2019 - May 20, 2019
Recommendation of Dividend of Rs. 4.50 per Equity Shares - May 17, 2019
JLL Standalone and Consolidated Results for the quarter and year ended March 31, 2019 - May 17, 2019
Newspaper Advertisement for Board Meeting - May 10, 2019
Schedule of Investor Conference Call - May 9, 2019
Notice of Board Meeting - May 9, 2019
Issuance of Commercial Paper of Rs. 100 Crore - April 18, 2019
Intimation to Stock Exchanges 2018 - 19
Q4 2018-19
Board Approval for revision in the Code of Practices and Procedures for Fair Disclosure - March 29, 2019
Redemption of Zero coupon convertible loan of IFC by JPL - March 29, 2019
Notice regarding closure of Trading Window - March 22, 2019
USFDA Inspection Update - API facility at Nanjangud - March 21, 2019
USFDA warning letter for Roorkee facility - March 8, 2019
Interest Payment on NCDs - March 6, 2019
Listing of Bond by JPL on Singapore Stock Exchange - March 6, 2019
Notice of Investor/ Analyst Meetings on March 6, 2019 - March 5, 2019
Issuance of Bond of US$200 million by JPL - March 5, 2019
Pricing and Rating of JPL Bond issue - February 28, 2019
Additional Information - JPL Bond Issue Proposal - February 25, 2019
JPL Bond Issue proposal - February 25, 2019
Issuance of Commercial Papers of Rs. 75 crore - February 20, 2019
Notice of Investor Meetings (Non-Deal Roadshow) - February 13, 2019
Notice of Record Date for Interest Payment on NCDs - February 6, 2019
Clarification regarding payment of Corporate Brand Royalty - February 5, 2019
Approval for payment of Corporate Brand Royalty to Jubilant Enpro Private Limited - February 5, 2019
Newspaper Advertisement for Q3 Results FY 2019 - February 4, 2019
JLL_Biosys_OCPS Conversion - February 1, 2019
JLL_Chemsys_OCPS Conversion - February 1, 2019
Q3 Results FY 2019 - February 1, 2019
Half Yearly Interest Payment on NCDs - January 28, 2019
Issuance of Commercial Papers of Rs. 100 Crore - January 25, 2019
Redemption and Final Interest Payment to NCD Holders - January 25, 2019
Notice of Board Meeting - January 25, 2019
Schedule for Investor Conference Call - January 25, 2019
Q3 2018-19
Record Date for redemption and payment of Interest on NCDs - December 31, 2018
Closure of Trading Window - December 21, 2018
Notice of Investor Meetings (Non-Deal Roadshow) - December 14, 2018
USFDA inspection update for solid dosage formulation facility at Roorkee - December 8, 2018
Acquisition of Common Stock in Inipharm Inc., USA - November 30, 2018
Disclosure regarding Acquisition of Equity Shares by DDDSL, Singapore - November 29, 2018
Intimation of Investor Meetings (Non-Deal Roadshow) - November 27, 2018
Upgrade in Credit Rating of JPL by S&P Global Ratings - November 2, 2018
Q2 Results FY 2019 - October 22, 2018
Newspaper Advertisement for Q2 Results FY 2019 - October 16, 2018
Notice of Board Meeting - October 15, 2018
Schedule for Investor Conference Call - October 15, 2018
Q2 2018-19
Voting Results of 40th Annual General Meeting - September 27, 2018
Proceedings of 40th Annual General Meeting - September 26 2018
Issue of NCDs - September 5, 2018
Newspaper Advertisement for 40th AGM - September 3, 2018
Notice of 40th Annual General Meeting - August 31, 2018
Credit Rating by India Ratings and Research - August 23, 2018
Newpaper Advertisement for results of Postal Ballot - August 8, 2018
Voting results of Postal Ballot and Scrutinizer's Report - August 7, 2018
Newspaper Advertisement for Q1 Results FY 2019 - July 30, 2018
Update of JPL IPO - July 27, 2018
Payment of Interest on NCDs - July 27, 2018
Q1 Results FY 2019 - July 27, 2018
Newpaper Advertisement for Board Meeting - July 21, 2018
Initiation of I-131 MIBG OPTIMUM Trials - July 20, 2018
Notice of Board Meeting - July 20, 2018
Schedule for Investor Conference Call - July 20, 2018
Notice of Postal Ballot - July 6, 2018
Notice for Record date and Interest Payment on NCDs - July 2, 2018
Q1 2018-19
Newspaper Advertisement for transfer of Equity Shares to IEPF - June 25, 2018
Credit Rating by CRISIL - June 25, 2018
Proposal to Consider Issue of NCDs - Junne 22, 2018
Notice for Schedule of Investor/Analyst meetings - June 11, 2018
Issuance of Commercial Papers of Rs. 75 crore - June 8, 2018
Disclosure in Form C under SEBI(PIT) Regulations, 2015 - June 4, 2018
Disclosure in Form C under SEBI(PIT) Regulations, 2015 - May 28, 2018
ANDA Approval for Niacin Extended-Release Tablets USP - May 15, 2018
Newspaper Advertisement for Audited Consoldated results for FY 2018 - May 10, 2018
Issuance of Commercial Papers of Rs. 80 Crore - May 10, 2018
Recommendation of Dividend of Rs. 3 per Equity Shares - May 9, 2018
Newspaper Advertisement for Board Meeting - May 3, 2018
Notice of Board Meeting - May 2, 2018
Update on SEBI Adjudication order - April 25, 2018
Issuance of Commercial Papers of Rs. 75 Crore - April 23, 2018
Intimation to Stock Exchanges 2017 - 18
Q4 2017-18
Notice of Investor/ Analyst Meetings - March 8, 2018
Stay of Order of Commissioner of State Excise, Maharashtra by Home Dept., Govt. of Maharashtra - March 7, 2018
Order of Commissioner of State Excise, Maharashtra - March 4, 2018
ANDA approval for Amantadine Hydrochloride Tablets - February 9, 2018
JLL Response on SEBI Order - February 1, 2018
Half Yearly Interest Payment on NCDs - January 29, 2018
Disclosure in Form C under SEBI(PIT) Regulations, 2015 - January 25, 2018
Newspaper Advertisement for Q3 Results FY 2018 - January 19, 2018
Issuance of Commercial Paper of Rs. 90 Crore - January 17, 2018
Changes in the Board of Directors - January 17, 2018
Newspaper Advertisement for Board Meeting - January 11, 2018
Notice of Board Meeting - January 10, 2018
Q3 2017-18
Half Yearly Interest Payment on NCDs - December 29, 2017
USFDA for DRAXIMAGE® DTPA - December 28, 2017
Share Acquisition by DDDSL - November 22, 2017
Issuance of Commercial Papers of Rs. 50 Crore
Newspaper Advertisement for Q2 Results FY 2018 - October 28, 2017
Certificate of Debenture Trustee - October 28, 2017
Notice of Board Meeting - October 18, 2017
Newspaper Advertisement for Board Meeting - October 18, 2017
es of
Issuance of Commercial Papers of Rs. 50 Crore - October 17, 2017
Q2 2017-18
Schedule of Investor Conference Call - October 18, 2017
Health Canada Approval - September 29, 2017
Notice of Investor/ Analyst Meetings - September 25, 2017
Notice for closure of Trading Window - September 21, 2017
Notice of Investor/ Analyst Meetings - September 19, 2017
Notice of Investor/ Analyst Meetings - September 4, 2017
Acquisition of Radiopharmacy business of Triad - September 1, 2017
Voting Results of 39th AGM - August 29, 2017
USFDA Approval for Indomethacin Capsules USP - August 28, 2017
USFDA Approval for Indomethacin Capsules USP - August 28, 2017
USFDA Approval for Drax Exametazime - August 21, 2017
USFDA approval for Tizanidine Hydrochloride Capsules - August 5, 2017
Newspaper Advertisement for transfer of Equity Shares to IEPF - August 4, 2017
Notice of Investor/ Analyst Meetings - August 1, 2017
Half Yearly Interest Payment on NCDs - July 28, 2017
Q1 Results FY 2018 - July 18, 2017
Half Yearly Interest Payment on NCDs - July 10, 2017
USFDA Approval for Bupropion Hydrochloride Extended-Release Tablets - July 6, 2017
Newspaper Advertisement for Board Meeting - July 5, 2017
Notice of Board Meeting - July 4, 2017
Q1 2017-18
Record Date for payment of Interest on NCDs - June 30, 2017
Notice for closure of Trading Window - June 21, 2017
NGT order for Gajraula Plant - June 1 , 2017
Vitamine B3 price increase update - May 25, 2017
Appointment of Directors - May 24, 2017
Half yearly certificate of Debenture Trustee - May 23, 2017
Recommendation of Dividend of Rs. 3 per Equity Shares - May 23, 2017
USFDA Approval for Amlodipine and Olmesartan Medoxomil Tablets - May 17, 2017
Newspaper Advertisement for Board Meeting - May 12, 2017
Notice of Board Meeting - May 11, 2017
NGT order for Gajraula Plant - May 9, 2017
Acquisition of Radiopharmacy business of Triad Isotopes - May 5, 2017
Newspaper Advertisement for transfer of Equity Shares to IEPF - May 3, 2017
Credit Rating by Crisil and India Ratings and Research Private Limited - May 2, 2017
Issuance of Commercial Papers of Rs. 75 Crore - April 27, 2017
NGT order for Cease of Operation at Gajraula Plant - April 27, 2017
USFDA Approval for Olmesartan Medoxmil Tables - April 25, 2017
Submission of documents with Debenture Trustee - April 24, 2017
Issuance of Commercial Papers of Rs. 100 Crore - April 18, 2017
Credit Rating by India Rating and Research Private Limited - April 13, 2017
Intimation to Stock Exchanges 2016 - 17
Q4 2016-17
USFDA approval for Celecoxib Capsules - April 6, 2017
Proposal to Consider Acquisition fo Specialty Pharma business in USA - March 21, 2017
Notice for closure of Trading Window - Marchr 15, 2017
Notice of Investor/ Analyst Meetings - February 28, 2017
Issuance of Commercial Papers of Rs. 40 Crore - February 28, 2017
USFDA Approval for Itraconaxole Capsules - February 27, 2017
Approval for Acquisition of OCPS of JBL - February 7, 2017
Changes in Board of Directors - February 7, 2017
Disclosure with details for Issue of NCDs - January 27, 2017
Issue of NCDs - January 27, 2017
Credit Rating from India Ratings &Research Private Limited - January 25, 2017
Issuance of Commercial Papers of Rs. 50 Crore - January 24, 2017
Newspaper advertisement for Board Meeting - January 20, 2017
Notice of Board Meeting - January 19, 2017
Issuance of Commercial Papers of Rs. 50 Crore - Janury 11, 2017
Issuance of Commercial Papers of Rs. 50 Crore - Janury 5, 2017
Announcement for signing of long term contract in Radiopharma business - January 4, 2017
Q3 2016-17
Closure of Trading Window - December 22, 2016
15% Price increse of Beta Picoline- December 20, 2016
Issuance of Commercial Papers of Rs. 50 Crore - November 25, 2016
Notice for Schedule of JPL Meeting - November 15, 2016
Clarification regarding issuance of Commercial Papers of Rs. 50 Crore - November 10, 2016
Issuace of Commercial Papers of Rs. 50 Crore - November 9, 2016
USFDA Approval for Darifenacin ER Tablets - October 13, 2016
USFDA Approval for Rosuvastatin Calcium Tablets - November 1, 2016
Proposal to consider issue of NCDs - October 24, 2016
Newspaper Advertisement for Board Meeting - October 19, 2016
Notice of Board Meeting - October 18, 2016
Issuace of Commercial Papers of Rs. 50 Crore - October 14, 2016
Disclsoure - October 13, 2016
Listing of Bond by JPL - October 7, 2016
JPL - Offering Memorandum
Completion of issue of Bonds by JPL - October 6, 2016
Australian approval for Lyophilized kit for the preparation of Tc 99m MAA Injection - October 5, 2016
Credit Rating by India Ratings & Research Private Limited - October 4, 2016
USFDA approval for RUBY-FILL®- Rubidium 82 Generator and Elution System - October 3, 2016
Q2 2016-17
Issue of Bond by JPL - September 29, 2016
Clarification by JLL - September 27, 2016
Proposal to issue bond by JPL - September 23, 2016
USFDA approval for Telmisartan tablets - August 24, 2016
Newspaper Advertisement for Board Meeting - July 28, 2016
Notice of Board Meeting - July 27, 2016
Q1 2016-17
Notice of Investor/ Analyst Meetings - June 28, 2016
Resignation of Director - May 24, 2016
Newspaper Advertisement for Board Meeting - May 11, 2016
Notice of Board Meeting - May 10, 2016
Investors
Financials
Quarterly Results
Investor Presentation
Annual Reports
Annual Return
Subsidiaries Accounts
Intimation to Stock Exchanges
Jubilant Pharmova Investor Meets
Stock Information
Share Price Graph
Historical Share Price
Analyst Coverage
Listing
Sub Division of Shares
Equity History
Investor Information
Change of Name
Scheme of Arrangement
Share Holding Pattern
Share Transfer Information
Distribution Pattern
Dividend Payment
Cost Spilit Letter
FAQs
Forms
Updation of KYC details
Credit Ratings
Corporate Governance
Philosophy
Board Structure
Policies and Codes
Duties of Directors
Postal Ballot
Unclaimed Dividend & Shares
Investor Feedback Form
Investor Contact
Nodal Officer
Institutional Investors
Investor Grievances
Registrar and Transfer Agent
KMP - Reg. 30
Investors Meet
Disclosure
Online Dispute Resolution